Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 507 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 Time to take on 9 new Cancer Grand Challenges March 8, 2023 The Largest Randomised Study to Date Points to Low Ipsilateral Breast... June 22, 2023 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Load more HOT NEWS Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... Why Cancer Survivors Should Have a Written Survivorship Care Plan She Faced Breast Cancer At 16 With Little Help From Doctors....
